Antitumor activity and pharmacodynamic biomarkers of a novel and orally available small-molecule antagonist of inhibitor of apoptosis proteins

Molecular Cancer Therapeutics

Volumn 12, Issue 2, 2013, Pages 230-240

  Sumi, Hiroyuki ^a   Yabuki, Masato ^a   Iwai, Kenichi ^a   Morimoto, Megumi ^a   Hibino, Ryosuke ^a   Inazuka, Masakazu ^a   Hashimoto, Kentaro ^a   Kosugi, Yohei ^a   Aoyama, Kazunobu ^a   Yamamoto, Shunsuke ^a   Yoshimatsu, Mie ^a   Yamasaki, Hideki ^a   Tozawa, Ryuichi ^a   Ishikawa, Tomoyasu ^a   Yoshida, Sei ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKERATIN 18; INHIBITOR OF APOPTOSIS PROTEIN; PROTEASOME; PROTEIN INHIBITOR; PYRROLO [1,2 A]PYRAZINE DERIVATIVE; T 3256336; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG POTENCY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN INTERACTION;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CASPASES; CELL LINE; CELL SURVIVAL; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; PYRAZINES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA; TUMOR NECROSIS FACTORS;

EID: 84873906475     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0699     Document Type: Article

References (44)

1. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000; 21: 485-95.
2. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435:677-81.
3. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 2004; 305:1471-4.
4. Crook NE, Clem RJ, Miller LK. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol 1993; 67:2168-74.
5. Srinivasula SM, Ashwell JD. IAPs: what's in a name? Mol Cell 2008; 30:123-35.
6. Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 1995; 83:1243-52.
7. Fotin-Mleczek M, Henkler F, Samel D, Reichwein M, Hausser A, Parmryd I, et al. Apoptotic crosstalk of TNF receptors: TNF-R2induces depletion of TRAF2 and IAP proteins and accelerates TNFR1-dependent activation of caspase-8. J Cell Sci 2002; 115:2757-70.
8. Deng Y, Ren X, Yang L, Lin Y, Wu X. A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell 2003; 115:61-70.
9. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3:401-10.
10. Riedl SJ, Renatus M, Schwarzenbacher R, Zhou Q, Sun C, Fesik SW. Structural basis for the inhibition of caspase-3 by XIAP. Cell 2001; 104:791-800.
11. Chai J, Shiozaki E, Srinivasula SM, Wu Q, Datta P, Alnemri ES. Structural basis of caspase-7 inhibition by XIAP. Cell 2001; 104: 769-80.
12. Suzuki Y, Nakabayashi Y, Nakata K, Reed JC, Takahashi R. X-linked inhibitor of apoptosis protein inhibits caspase-3 and -7 in distinct modes. J Biol Chem 2001; 276:27058-63.
13. Jaffer S, Orta L, Sunkara S, Sabo E, Burstein DE. Immunohistochemical detection of antiapoptotic protein X-linked inhibitor of apoptosis in mammary carcinoma. Hum Pathol 2007; 38:864-70.
14. Imoto I, Tsuda H, Hirasawa A, Miura M, Sakamoto M, Hirohashi S, et al. Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. Cancer Res 2002; 62: 4860-6.
15. Nakagawa Y, Abe S, Kurata M, Hasegawa M, Yamamoto K, Inoue M, et al. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol 2006; 81:824-31.
16. Kluger HM, McCarthy MM, Alvero AB, Sznol M, Ariyan S, Camp RL, et al. The X-linked inhibitor of apoptosis protein is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with carboplatin sensitization. J Transl Med 2007; 5:6.
17. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis and their emerging role in cancer. Oncogene 1998; 17: 3247-59.
18. Fulda S. Inhibitor of apoptosis proteins as targets for anticancer therapy. Expert Rev Anticancer Ther 2007; 7:1255-64.
19. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102:33-42.
20. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102: 43-53.
21. Liu Z, Sun C, Olejniczak ET, Meadows RP, Betz SF, Oost T, et al. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 2000; 408:1004-8.
22. Wu G, Chai J, Suber TL, Wu JW, Du C, Wang X, et al. Structural basis of IAP recognition by Smac/DIABLO. Nature 2000; 408:1008-12.
23. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007; 131:669-81.
24. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007; 131:682-93.
25. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J, et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007; 12: 445-56.
26. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008; 133:693-703.
27. Al-Shamahi A, Murch L, Kirkham K. American Society of Clinical Oncology-46th annual meeting. IDrugs 2010; 13:506-9.
28. Cai Q, Sun H, Peng Y, Lu J, Nikolovska-Coleska Z, McEachern D, et al. A potent and orally active antagonist SM-406/AT-406 of multiple inhibitor of apoptosis proteins in clinical development for cancer treatment. J Med Chem 2011; 54:2714-26.
29. Weisberg E, Ray A, Barrett R, Nelson E, Christie AL, Porter D, et al. Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia 2010; 24:2100-9.
30. Flygare JA, Beresini M, Budha N, Chan H, Chan IT, Cheeti S, et al. Discovery of a potent small-molecule antagonist of inhibitor of apoptosis proteins and clinical candidate for the treatment of cancer. J Med Chem 2012; 55:4101-13.
31. Hashimoto K, Ishikawa T, Yuga O, inventors; Takeda Pharmaceutical Company Ltd., assignee. Alanine derivatives as inhibitors of apoptosis proteins. WIPO patent WO/2011/016576. 2011 Feb 10.
32. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002; 40:403-39.
33. Lane EB, Alexander CM. Use of keratin antibodies in tumor diagnosis. Semin Cancer Biol 1990; 1:165-79.
34. Hatzfeld M, Franke WW. Pair formation and promiscuity of cytokeratins: formation in vitro of heterotypic complexes and intermediatesized filaments by homologous and heterologous recombinations of purified polypeptides. J Cell Biol 1985; 101:1826-41.
35. Steinert PM, Roop DR. Molecular and cellular biology of intermediate filaments. Annu Rev Biochem 1988; 57:593-625.
36. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, Steiner G. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004; 64:1751-6.
37. BivenK, Erdal H, HaggM, Ueno T, Zhou R, LynchM, et al. A novelassay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis 2003; 8:263-8.
38. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 1999; 187: 567-72.
39. Schutte B, Henfling M, Kolgen W, Bouman M, Meex S, Leers MP, et al. Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res 2004; 297:11-26.
40. Micha D, Cummings J, Shoemaker A, Elmore S, Foster K, Greaves M, et al. Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer. Clin Cancer Res 2008; 14:7304-10.
41. Demiray M, Ulukaya EE, Arslan M, Gokgoz S, Saraydaroglu O, Ercan I, et al. Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer Invest 2006; 24:669-76.
42. Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer 2007; 56:399-404.
43. Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M, et al. cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell 2011; 43:449-63.
44. Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, et al. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell 2011; 43:432-48.